These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

831 related articles for article (PubMed ID: 29703207)

  • 1. SGLT2 inhibition via dapagliflozin improves generalized vascular dysfunction and alters the gut microbiota in type 2 diabetic mice.
    Lee DM; Battson ML; Jarrell DK; Hou S; Ecton KE; Weir TL; Gentile CL
    Cardiovasc Diabetol; 2018 Apr; 17(1):62. PubMed ID: 29703207
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Glycemic control by the SGLT2 inhibitor empagliflozin decreases aortic stiffness, renal resistivity index and kidney injury.
    Aroor AR; Das NA; Carpenter AJ; Habibi J; Jia G; Ramirez-Perez FI; Martinez-Lemus L; Manrique-Acevedo CM; Hayden MR; Duta C; Nistala R; Mayoux E; Padilla J; Chandrasekar B; DeMarco VG
    Cardiovasc Diabetol; 2018 Jul; 17(1):108. PubMed ID: 30060748
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dapagliflozin acutely improves endothelial dysfunction, reduces aortic stiffness and renal resistive index in type 2 diabetic patients: a pilot study.
    Solini A; Giannini L; Seghieri M; Vitolo E; Taddei S; Ghiadoni L; Bruno RM
    Cardiovasc Diabetol; 2017 Oct; 16(1):138. PubMed ID: 29061124
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sodium-glucose cotransporter 2 inhibitor Dapagliflozin attenuates diabetic cardiomyopathy.
    Arow M; Waldman M; Yadin D; Nudelman V; Shainberg A; Abraham NG; Freimark D; Kornowski R; Aravot D; Hochhauser E; Arad M
    Cardiovasc Diabetol; 2020 Jan; 19(1):7. PubMed ID: 31924211
    [TBL] [Abstract][Full Text] [Related]  

  • 5. SGLT2 inhibition with empagliflozin improves coronary microvascular function and cardiac contractility in prediabetic ob/ob
    Adingupu DD; Göpel SO; Grönros J; Behrendt M; Sotak M; Miliotis T; Dahlqvist U; Gan LM; Jönsson-Rylander AC
    Cardiovasc Diabetol; 2019 Feb; 18(1):16. PubMed ID: 30732594
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Combined SGLT2 and DPP4 Inhibition Reduces the Activation of the Nlrp3/ASC Inflammasome and Attenuates the Development of Diabetic Nephropathy in Mice with Type 2 Diabetes.
    Birnbaum Y; Bajaj M; Yang HC; Ye Y
    Cardiovasc Drugs Ther; 2018 Apr; 32(2):135-145. PubMed ID: 29508169
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of 12-week treatment with dapagliflozin and gliclazide on faecal microbiome: Results of a double-blind randomized trial in patients with type 2 diabetes.
    van Bommel EJM; Herrema H; Davids M; Kramer MHH; Nieuwdorp M; van Raalte DH
    Diabetes Metab; 2020 Apr; 46(2):164-168. PubMed ID: 31816432
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Gut Microbiota-Tryptophan Metabolism-GLP-1 Axis Participates in β-Cell Regeneration Induced by Dapagliflozin.
    Jiang Y; Yang J; Xia L; Wei T; Cui X; Wang D; Jin Z; Lin X; Li F; Yang K; Lang S; Liu Y; Hang J; Zhang Z; Hong T; Wei R
    Diabetes; 2024 Jun; 73(6):926-940. PubMed ID: 38471012
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Butyrate attenuated fat gain through gut microbiota modulation in db/db mice following dapagliflozin treatment.
    Oh TJ; Sul WJ; Oh HN; Lee YK; Lim HL; Choi SH; Park KS; Jang HC
    Sci Rep; 2019 Dec; 9(1):20300. PubMed ID: 31889105
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dapagliflozin Modulates the Fecal Microbiota in a Type 2 Diabetic Rat Model.
    Yang M; Shi FH; Liu W; Zhang MC; Feng RL; Qian C; Liu W; Ma J
    Front Endocrinol (Lausanne); 2020; 11():635. PubMed ID: 33312157
    [No Abstract]   [Full Text] [Related]  

  • 11. The Effect of Sodium-Dependent Glucose Cotransporter 2 Inhibitor Tofogliflozin on Neurovascular Coupling in the Retina in Type 2 Diabetic Mice.
    Hanaguri J; Yokota H; Kushiyama A; Kushiyama S; Watanabe M; Yamagami S; Nagaoka T
    Int J Mol Sci; 2022 Jan; 23(3):. PubMed ID: 35163285
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Amelioration of diastolic dysfunction by dapagliflozin in a non-diabetic model involves coronary endothelium.
    Cappetta D; De Angelis A; Ciuffreda LP; Coppini R; Cozzolino A; Miccichè A; Dell'Aversana C; D'Amario D; Cianflone E; Scavone C; Santini L; Palandri C; Naviglio S; Crea F; Rota M; Altucci L; Rossi F; Capuano A; Urbanek K; Berrino L
    Pharmacol Res; 2020 Jul; 157():104781. PubMed ID: 32360273
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Nephropathy in diabetic db/db mice is accelerated by high protein diet and improved by the SGLT2 inhibitor dapagliflozin.
    Nørgaard SA; Briand F; Sand FW; Galsgaard ED; Søndergaard H; Sørensen DB; Sulpice T
    Eur J Pharmacol; 2019 Oct; 860():172537. PubMed ID: 31310751
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Melatonin ameliorates SGLT2 inhibitor-induced diabetic ketoacidosis by inhibiting lipolysis and hepatic ketogenesis in type 2 diabetic mice.
    Park JH; Seo I; Shim HM; Cho H
    J Pineal Res; 2020 Mar; 68(2):e12623. PubMed ID: 31743484
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tauroursodeoxycholic Acid Reduces Arterial Stiffness and Improves Endothelial Dysfunction in Type 2 Diabetic Mice.
    Battson ML; Lee DM; Jarrell DK; Hou S; Ecton KE; Phan AB; Gentile CL
    J Vasc Res; 2017; 54(5):280-287. PubMed ID: 28930750
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sodium glucose co-transporter 2 (SGLT2) inhibition via dapagliflozin improves diabetic kidney disease (DKD) over time associatied with increasing effect on the gut microbiota in db/db mice.
    Wu J; Chen Y; Yang H; Gu L; Ni Z; Mou S; Shen J; Che X
    Front Endocrinol (Lausanne); 2023; 14():1026040. PubMed ID: 36777358
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ramipril improves oxidative stress-related vascular endothelial dysfunction in db/db mice.
    Liang W; Tan CY; Ang L; Sallam N; Granville DJ; Wright JM; Laher I
    J Physiol Sci; 2008 Dec; 58(6):405-11. PubMed ID: 18845058
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dapagliflozin Does Not Modulate Atherosclerosis in Mice with Insulin Resistance.
    Taberner-Cortés A; Vinué Á; Herrero-Cervera A; Aguilar-Ballester M; Real JT; Burks DJ; Martínez-Hervás S; González-Navarro H
    Int J Mol Sci; 2020 Dec; 21(23):. PubMed ID: 33287201
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dapagliflozin attenuates human vascular endothelial cell activation and induces vasorelaxation: A potential mechanism for inhibition of atherogenesis.
    Gaspari T; Spizzo I; Liu H; Hu Y; Simpson RW; Widdop RE; Dear AE
    Diab Vasc Dis Res; 2018 Jan; 15(1):64-73. PubMed ID: 28976221
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sodium-glucose cotransporter 2 inhibitors attenuate vascular calcification by suppressing endoplasmic reticulum protein thioredoxin domain containing 5 dependent osteogenic reprogramming.
    Wu S; Luo X; Chen Y; Wang Z; Liu X; Sun N; Zhao J; Luo W; Zhang J; Tong X; Huang L; Liu C; Qin Z
    Redox Biol; 2024 Jul; 73():103183. PubMed ID: 38759418
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 42.